Inflammation of the Eye
📧 Sign up to get email alerts when something new happens for Inflammation of the Eye.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Results: A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery [Phase 3]
Phase 3 trial evaluating OCS-01 ophthalmic suspension versus vehicle for ocular inflammation and pain after cataract surgery; study terminat…
-
FDA approval · 2026-01-26FDA Approved: DIFLUPREDNATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' difluprednate ophthalmic emulsion 0.05% as a generic version for treating inflammation of the eye and …
-
FDA approval · 2025-02-11FDA Approved: DIFLUPREDNATE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved the original application for difluprednate from Upsher-Smith Laboratories, enabling a generic ophthalmic corticosteroid for pos…
-
FDA approval · 2024-05-24FDA Approved: FLAREX — Supplemental Application (Eyevance Pharmaceuticals)
FDA approved a supplemental application for FLAREX (fluorometholone acetate) from Eyevance Pharmaceuticals.
-
FDA approval · 2024-01-09FDA Approved: FLUOROMETHOLONE OPHTHALMIC SUSPENSION — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC’s fluorometholone ophthalmic suspension under an Original Application (ANDA216348).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-02-11FDA Approved: TOBRAMYCIN AND DEXAMETHASONE — Original Application (Padagis US LLC)
The FDA approved Padagis US LLC's generic Tobramycin and Dexamethasone ophthalmic suspension as an original ANDA for treatment of inflammati…
-
FDA approval · 2021-12-10FDA Approved: MAXIDEX — Supplemental Application (Harrow Eye, LLC)
FDA approved a supplemental application for MAXIDEX (dexamethasone) by Harrow Eye, LLC.
-
FDA approval · 2021-02-26FDA Approved: LOTEPREDNOL ETABONATE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' Loteprednol etabonate as an Original Application (ANDA) for ophthalmic use.
-
CLINICAL_TRIALS trial_result · 2020-09-03Clinical Trial Update: Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery [Phase 3]
Phase 3 trial update for loteprednol etabonate ophthalmic gel in treating ocular inflammation and pain after cataract surgery has completed …
-
FDA approval · 2020-02-07FDA Approved: NEOMYCIN POLYMYXIN B SULFATES AND DEXAMETHASONE — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for Maxitrol (neomycin sulfate, polymyxin B sulfate, and dexamethasone) by Bausch & Lomb Incorporate…
-
CLINICAL_TRIALS trial_result · 2019-05-24Clinical Trial Update: A Clinical Study to Assess the Efficacy and Safety of Dexamethasone Suspension for Cataract Surgery [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating the efficacy and safety of dexamethasone suspension for inflammation associated with catarac…
-
FDA approval · 2017-12-18FDA Approved: MAXITROL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for MAXITROL (neomycin sulfate, polymyxin B sulfate and dexamethasone) from Novartis Pharmaceuticals…
-
FDA approval · 2016-03-10FDA Approved: MAXIDEX — Supplemental Application (Harrow Eye, LLC)
FDA approved a supplemental application for MAXIDEX (dexamethasone) from Harrow Eye, LLC.
-
FDA approval · 2013-10-09FDA Approved: LOTEPREDNOL ETABONATE — Supplemental Application (Bausch & Lomb Americas Inc.)
FDA approved a supplemental application for Loteprednol etabonate (Lotemax) by Bausch & Lomb Americas Inc., approving changes to the product…
-
FDA label_change · 2013-05-15FDA Approved: DIFLUPREDNATE OPHTHALMIC — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for difluprednate ophthalmic from Sandoz, updating labeling (new indication or labeling changes)…
-
FDA approval · 2013-02-12FDA Approved: FML — Supplemental Application (Allergan, Inc.)
FDA approved Allergan's supplemental application for FML (fluorometholone), resulting in updated labeling for the ophthalmic corticosteroid.
-
FDA approval · 2013-02-12FDA Approved: FML FORTE — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for FML Forte (fluorometholone) from Allergan, indicating an approved update to the product's ND…
-
FDA approval · 2011-04-15FDA Approved: LOTEMAX — Original Application (Bausch & Lomb Incorporated)
FDA approved Lotemax (loteprednol etabonate) under Original Application (NDA200738) for ophthalmic use to treat inflammatory conditions of t…
-
FDA approval · 2008-06-23FDA Approved: DIFLUPREDNATE OPHTHALMIC — Original Application (Sandoz Inc)
FDA approved the original application for difluprednate ophthalmic from Sandoz, a corticosteroid eye drop for ocular inflammation associated…
-
FDA approval · 2006-08-07FDA Approved: LOTEPREDNOL ETABONATE AND TOBRAMYCIN — Supplemental Application (Bausch & Lomb Americas Inc.)
The FDA approved a supplemental application for the ophthalmic combination Loteprednol etabonate and tobramycin (brand Zylet) from Bausch & …